GSA Capital Partners LLP Sells 18,375 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

GSA Capital Partners LLP reduced its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 37.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,992 shares of the company’s stock after selling 18,375 shares during the period. GSA Capital Partners LLP’s holdings in Elanco Animal Health were worth $455,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Benjamin F. Edwards & Company Inc. lifted its holdings in Elanco Animal Health by 337.7% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after purchasing an additional 1,361 shares during the last quarter. ORG Wealth Partners LLC acquired a new stake in Elanco Animal Health during the 3rd quarter worth approximately $29,000. nVerses Capital LLC acquired a new stake in Elanco Animal Health during the 2nd quarter worth approximately $32,000. ORG Partners LLC acquired a new stake in Elanco Animal Health during the 2nd quarter worth approximately $31,000. Finally, Quarry LP acquired a new stake in Elanco Animal Health during the 2nd quarter worth approximately $40,000. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Trading Up 1.0 %

NYSE ELAN opened at $13.44 on Thursday. The business’s 50-day moving average price is $13.74 and its two-hundred day moving average price is $14.76. Elanco Animal Health Incorporated has a 12 month low of $11.40 and a 12 month high of $18.80. The firm has a market capitalization of $6.64 billion, a PE ratio of 33.60, a price-to-earnings-growth ratio of 1.46 and a beta of 1.41. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the previous year, the company posted $0.18 EPS. The business’s revenue was down 3.6% on a year-over-year basis. On average, analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analyst Ratings Changes

ELAN has been the subject of several analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Elanco Animal Health in a report on Thursday, September 19th. Morgan Stanley cut Elanco Animal Health from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $17.00 to $15.00 in a report on Thursday, September 19th. Finally, Barclays boosted their price target on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Hold” and an average target price of $17.14.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.